Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus

December 2009
International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p122
Academic Journal
The abnormal production of autoantibodies is responsible for the pathology in systemic lupus erythematosus (SLE). It is known that regulatory T cells (Tregs ) can inhibit antibody production by suppression of T helper cells. In this study, it was demonstrated that natural Tregs inhibit B cell activity in vitro and in vivo in SLE through cell contact-mediated mechanisms that directly suppress autoantibody-producing B cells.


Related Articles

  • Similar CD19 Dysregulation in Two Autoantibody-Associated Autoimmune Diseases Suggests a Shared Mechanism of B-Cell Tolerance Loss. DONNA CULTON; MATILDA NICHOLAS; DONNA BUNCH; QUAN ZHEN; THOMAS KEPLER; MARY DOOLEY; CHANDRA MOHAN; PATRICK NACHMAN // Journal of Clinical Immunology;Jan2007, Vol. 27 Issue 1, p53 

    ???We report here that dysregulation of CD19, a coreceptor that augments B-cell receptor (BCR) signaling, occurs at two B-cell differentiative stages in patients with systemic lupus erythematosus (SLE) and antineutrophil cytoplasmic autoantibody (ANCA) associated small vessel vasculitis (SVV)....

  • 60 kD Ro and nRNP A Frequently Initiate Human Lupus Autoimmunity. Heinlen, Latisha D.; McClain, Micah T.; Ritterhouse, Lauren L.; Bruner, Benjamin F.; Edgerton, Colin C.; Keith, Michael P.; James, Judith A.; Harley, John B. // PLoS ONE;2010, Vol. 5 Issue 3, p1 

    Systemic lupus erythematosus (SLE) is a clinically heterogeneous, humoral autoimmune disorder. The unifying feature among SLE patients is the production of large quantities of autoantibodies. Serum samples from 129 patients collected before the onset of SLE and while in the United States...

  • Origin and structure of autoantibodies and antigens in autoimmune rheumatic diseases. Rahman, A.; Stoliar, B. D. // Lupus;2008, Vol. 17 Issue 3, p232 

    The article explores on the study of autoantibodies and antigens in autoimmune disease. The study is designed to examine the nature and structure of autoantibodies on the development of autoimmune rheumatic disease. It discusses the early stages of the immune response of systemic lupus...

  • Relationship of Interleukin-12 and Interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus. Spadaro, A.; Scrivo, R.; Bombardieri, M.; Riccieri, V.; Rinaldi, T.; Taccari, E.; Valesini, G. // Clinical Rheumatology;May2003, Vol. 22 Issue 2, p107 

    The aim of the study was to evaluate whether the imbalance between IL-12 and IL-13 serum levels, reflecting Th1/Th2 activity, is related to class-specific circulating rheumatoid factors (RF) and anticardiolipin (aCL) antibodies in SLE. Using ELISA we measured serum IL-12, IL-13, RF and aCL...

  • B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Podolskaya, A.; Stadermann, M.; Pilkington, C.; Marks, S. D.; Tullus, K. // Archives of Disease in Childhood;May2008, Vol. 93 Issue 5, p401 

    Objective: B cell dysregulation is involved in the development of childhood-onset systemic lupus erythematosus (SLE). The safety and efficacy of B cell depletion therapy is evaluated in the the largest series of children to be presented in the literature. Methods: 19 children (89% female) with...

  • Phenotyping of P105-Negative B Cell Subsets in Patients with Systemic Lupus Erythematosus. Koarada, Syuichi; Tada, Yoshifumi; Suematsu, Rie; Soejima, Sachiko; Inoue, Hisako; Ohta, Akihide; Nagasawa, Kohei // Clinical & Developmental Immunology;2012, p1 

    This study aimed to investigate phenotype of RP105(-) B cell subsets in patients with systemic lupus erythematosus (SLE). Flow cytometry was used for phenotyping RP105-negaive B cell subsets. Based on CD19, RP105, and CD138 expression, RP105(-) B cells consist of at least 5 subsets of late B...

  • Inhibition of follicular T-helper cells by CD8+ regulatory T cells is essential for self tolerance. Hye-Jung Kim; Verbinnen, Bert; Xiaolei Tang; Linrong Lu; Cantor, Harvey // Nature;9/16/2010, Vol. 467 Issue 7313, p328 

    The ability to produce vigorous immune responses that spare self tissues and organs depends on the elimination of autoreactive T and B cells. However, purging of immature and mature self-reactive T and B cells is incomplete and may also require the involvement of cells programmed to suppress...

  • Omalizumab for Urticarial Vasculitis: Case Report and Review of the Literature. Ghazanfar, Misbah Nasheela; Thomsen, Simon Francis // Case Reports in Dermatological Medicine;9/8/2015, Vol. 2015, p1 

    Urticarial vasculitis is characterised by inflamed itching or burning red patches or wheals that resemble urticaria but persist for greater than 24 hours. It is often idiopathic but is sometimes associated with collagen-vascular disease, particularly systemic lupus erythematosus. Treatment...

  • Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity. Robak, E.; Robak, T. // Current Medicinal Chemistry;Jan2012, Vol. 19 Issue 3, p438 

    Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B cell hyperactivity and defective T-cell function, and several cytokine aberrations, with high titer production of autoantibodies and clinical involvement in multiple organ systems. It can present with a wide variety...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics